Universitat Zurich
34 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 14 name spellings.
33
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 28 to 30, 2026 · next Nov 28
- 2 fees due Dec 20 to 27, 2026 · next Dec 20
- 2 fees due Jan 4 to 9, 2027 · next Jan 4
- 3 fees due Feb 13 to 25, 2027 · next Feb 13
- 1 fee due Mar 24, 2027The maintenance fee for Band-pass filter (US 10,425,063) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 2 fees due Apr 17 to 22, 2027 · next Apr 17
- 2 fees due May 12 to 17, 2027 · next May 12
- 2 fees due Jun 24 to 26, 2027 · next Jun 24
- 2 fees due Jul 21 to 28, 2027 · next Jul 21
- 3 fees due Aug 11 to 18, 2027 · next Aug 11
- 3 fees due Sep 1 to 29, 2027 · next Sep 1
- 7 fees due Oct 2 to 30, 2027 · next Oct 2
Recent changes
- 3 of the patents on this record were granted since Aug 21, 2026
- Nov 10 US 12,791,560 A Method for Determining the Likelihood of a Patient Being Responsive to Cancer Immunotherapy
- Nov 3 US 12,782,312 Neurocomputational Electrochemical Sensing Device for Predicting Properties of a Substance
- Nov 3 US 12,780,942 ARTC1 Ligands for Cancer Treatment
- 3 terms have ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,838,496 | Template-fixed peptidomimetics as medicaments against HIV and cancer In force · USPTO record | In force | USPTO record | |
| US 7,430,675 | Anticipatory Power Management for Battery-Powered Electronic Device In force · High confidence | In force | High confidence | |
| US 10,144,765 | Template-Fixed Peptidomimetics In force · Medium confidence | In force | Medium confidence | |
| US 8,921,325 | Template-Fixed Peptidomimetics In force · High confidence | In force | High confidence | |
| US 7,687,646 | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof In force · USPTO record | In force | USPTO record | |
| US 9,828,420 | Method of Providing Disease-Specific Binding Molecules and Targets In force · High confidence | In force | High confidence | |
| US 10,131,708 | Methods of Treating Alzheimer's Disease In force · High confidence | In force | High confidence | |
| US 10,202,445 | Method of providing disease-specific binding molecules and targets In force · USPTO record | In force | USPTO record | |
| US 9,260,692 | Use of modified cells for the treatment of multiple sclerosis In force · USPTO record | In force | USPTO record | |
| US 9,944,952 | Replication-defective arenavirus vectors In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 162: 34 patents in force now held by others · 102 lapsed for an unpaid fee · 55 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
42 pending · 35 abandoned · 94 no status recorded